涉嫌“傳毒”,金域醫學(603882.SH)連續第四日下跌
格隆匯1月14日丨國內最大的第三方醫學檢驗機構金域醫學(603882.SH)股價已連續第四日下跌,今日盤中一度跌至81.23元,股價創2020年11月以來新低,4日累跌超11%,最新市值跌破400億元。1月12日,許昌警方通報,金域醫學子公司鄭州金域區域負責人張某東,違反傳染病防治法的規定,實施引起新冠病毒傳播或有傳播嚴重危險的行為。已於10日對其以涉嫌刑事犯罪立案偵查並採取強制措施。截至目前,張某東到底做了什麼,警方和金域方面均未明確,外界對此議論紛紛。期間出現了“主動傳播病毒”“丟失樣本”“偽造數據”“瞞報數據”等傳言,但金域醫學通過官微均對此進行了否認。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.